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Translational Relevance 
This is the first study to examine the ability of the Breast Cancer Index to re-stratify 
discrepant risk groups for distant recurrence by the Oncotype Recurrence Score. 
The study was conducted in a set of 665 postmenopausal women with lymph node 
negative, hormone receptor positive breast cancer treated with either tamoxifen or 
anastrozole alone. Our results show that the Breast Cancer Index re-stratifies 
women with low or intermediate risk for distant recurrence by the Recurrence Score 
into clinically relevant different risk groups with significantly different risk of distant 
recurrence at 10 years of follow-up. In contrast, the Recurrence Score did not 
significantly re-stratify any patients into different risk categories. Our results showed 
that the prognostic value of BCI may have potential clinical impact in terms of 
improving individualized risk stratification for patients with lymph-node negative early 
stage breast cancer. 
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Abstract 
Background: Previous results from the TransATAC study demonstrated that both 
the Breast Cancer Index (BCI) and the OncotypeDX Recurrence Score (RS) added 
significant prognostic information to clinicopathologic factors over a 10-year period. 
Here, we examined cross-stratification between BCI and RS to directly compare their 
prognostic accuracy at the individual patient level. 
Patients and methods: 665 patients with hormone receptor positive (HR+) and 
lymph-node negative disease were included in this retrospective analysis. BCI and 
RS risk groups were determined using pre-defined clinical cut-points. Kaplan-Meier 
estimates of 10-year risk of distant recurrence (DR) and log-rank tests were used to 
examine cross-stratification between BCI and RS. 
Results: As previously reported, both RS and BCI were significantly prognostic in 
years 0 to 10. BCI provided significant additional prognostic information to the 
Clinical Treatment Score (CTS)CTS plus RS (∆LR-χ2=11.09; P<0.001) whereas no 
additional prognostic information was provided by RS to CTS plus BCI (∆LR-χ2=2.22; 
P=0.1). Re-stratification by BCI of the low and intermediate RS risk groups led to 
subgroups with significantly different DR rates (P<0.001 and P=0.003, respectively). 
In contrast, re-stratified subgroups created by re-stratification by RS of BCI risk 
groups did not differ significantly. 
Conclusions: In this retrospective analysis, BCI demonstrated increased prognostic 
accuracy versus RS. Notably, BCI identified subsets of RS low and RS intermediate 
risk patients with significant and clinically relevant rates of DR. These results indicate 
that additional subsets of women with HR+, lymph-node negative breast cancer 
identified by BCI may be suitable candidates for adjuvant chemotherapy or extended 
endocrine therapy. 
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Introduction 
Breast cancer is the most common cancer and the second leading cause of cancer-
related death in women worldwide [1]. As a result of significant advancements in the 
molecular characterization of breast cancer etiology, clinical management has 
evolved to include a comprehensive assessment of the underlying biology of the 
patient’s tumor alongside the clinicopathological paradigm to determine treatment 
strategies [2, 3]. The ongoing challenge in breast cancer is the effective treatment of 
a heterogeneous disease associated with a wide spectrum of morphologic and 
molecular subtypes with variable outcomes [3]. 
Genomic tools and expression-based multi-gene signatures have increased 
prognostic information for early stage breast cancer patients beyond traditional 
clinicopathological factors [4-6]. The 21-gene based Recurrence Score 
(OncotypeDX; RS) is a well-established multi-gene assay, which was developed to 
assess the risk of distant recurrence in women with hormone receptor positive, node-
negative breast cancer treated with tamoxifen [7]. The RS classifies women into low 
(RS<18), intermediate (RS: 18-30), and high (RS>30) risk groups for distant 
recurrence (DR). The RS has been validated and evaluated in a number of clinical 
trials, and results confirm the prognostic value of RS beyond that of clinical 
parameters for DR in the first five years after diagnosis [7-9]. The Breast Cancer 
Index (BCI) is a second generation gene expression signature developed from the 
combination of two biomarkers: the HOXB13:IL17BR expression ratio (H/I) and the 
Molecular Grade Index (MGI) [10]. H/I is a biomarker that is associated with tumor 
responsiveness to endocrine therapy in breast cancer [10, 11]. MGI consists of the 
average expression of five cell cycle-associated genes and provides quantitative and 
5 
 
objective molecular assessment of tumor grade and proliferative status [10, 12]. The 
linear, but not cubic, BCI score provides an estimate for a patient’s risk for DR and 
stratifies patients into different risk groups in the early (year 0-5), late (year 5-10) and 
overall (year 0-10) time periods [10, 13]. 
 
In a previous study, the linear BCI score was shown to provide more prognostic 
information for distant recurrence than RS [13]. However, in women with discrepant 
scores their values have not been evaluated to date. Here, we investigate the 
comparative prognostic strength, agreement and clinical significance of cross 
stratification by the RS and BCI. 
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Methods 
Study population 
The translational Arimidex, Tamoxifen Alone or Combination (TransATAC) study 
collected formalin-fixed paraffin embedded (FFPE) blocks from women with hormone 
receptor positive breast cancer who did not receive chemotherapy as part of their 
initial treatment, and who were randomised to either anastrozole or tamoxifen [14]. 
For this analysis, only women with lymph node-negative disease and data on both 
molecular scores have been included (N=665). 
Analytical methods 
Analytical methods for RS and BCI (linear model) have been described in detail 
previously [5, 6, 14]. In brief, RNA was extracted by Genomic Health and gene 
expression analysis for both scores was done by real time RT-PCR. Risk 
stratification with RS and BCI was based on pre-specified cut-off points for 10-year 
risk of DR: RS <18: low risk, 18-31: intermediate risk, >31: high risk, and BCI 
<5.0825: low risk, 5.0825-6.5025: intermediate risk, >6.5025: high risk. 
Statistical analyses 
The primary objective of this analysis was to determine the differential risk of DR for 
women with discrepant RS and BCI scores. The primary endpoint for the comparison 
was time to DR with death before DR being treated as a censoring event. The 
association between the risk score/categories and distant recurrence was assessed 
using hazard ratios (HR) derived from Cox proportional hazard models with 
associated 95% Confidence Intervals (CI). HR for the continuous risk scores were 
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computed for a difference between the 25th and 75th percentile of the continuous 
scores (interquartile HR). 
For multivariate analyses, each score was combined with the Clinical Treatment 
Score (CTS, an algorithm combining nodal status, tumor size, grade, age and 
treatment) to determine the added prognostic information in that score. Changes in 
likelihood ratio values (∆LR-χ2) were used to measure and compare the relative 
amount of information of one score compared to the other. The Net Reclassification 
Index (NRI) was used to determine the net improvement in prognostic prediction by 
BCI compared to the RS for patients with and without DR. P-values were two-sided, 
based on normal approximation and all confidence intervals (CI) were at the 95% 
level. Analyses were performed using STATA version 13.1 (College Station, Texas 
USA). 
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Results 
665 postmenopausal women with HR+, lymph-node negative disease have been 
included in this retrospective analysis. Of these, 72 (10.8%) had a DR before 10 
years of follow-up. Detailed baseline characteristics for this study group have been 
published previously [13]. In brief, median age was 62.4 years (IQR 46.7 to 88.4), 
most women had moderately differentiated tumors (51.7%), and tumor size of less or 
equal to 2cm (73.1%). 
 
Table 1 shows Hazard Ratios and prognostic information provided (LR-χ2) by each 
score and in addition to the CTS and the other score (∆LR-χ2). There was a 
significant effect of adding BCI to CTS plus RS (∆LR-χ2=11.09, P=0.0009) whereas 
no additional prognostic information to the CTS plus BCI was added by the RS (∆LR-
χ2=2.22, P=0.1). Table 2 shows the cross-stratification by RS and BCI into the 
respective risk groups. Overall, BCI classified fewer women into intermediate risk 
(25.0% vs. 26.8%) but more patients into high risk than RS (16.4% vs. 14.9%). In 
total, 283 (42.6%) women were classified into the low, 49 (7.4%) into the 
intermediate, and 55 (8.3%) into high risk groups by both BCI and RS, leading to a 
concordance of 58.2% between RS and BCI risk categories (Table 2). Among the 
278 (41.8%) discordant cases, 24.414.3% of BCI low risk patients were re-stratified 
into RS-intermediate and 3.11.8% into RS-high risk groups (Table 2). In contrast, 
BCI re-classified 21.912.8% and 5.23.0% of RS-low risk patients as BCI-intermediate 
and BCI-high risk, respectively (Table 2). 
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Net Reclassification Index (NRI) was used to evaluate the incremental risk prediction 
improvement achieved by BCI as compared to RS for DR and non-events groups, 
separately (Table 3). For those with DR, the BCI classified 21 women into higher and 
14 into lower risk categories compared to the RS (Table 3). This translates into a net 
reclassification of 9.7% by BCI for women with a DR. For non-events, BCI re-
classified 125 women into lower and 118 into higher risk categories than RS, 
resulting in a net reclassification of only 1.2% by BCI. The overall NRI for BCI vs. RS 
was 10.9%, which was statistically significant (P=0.001) (Table 3). 
The comparison of prognostic accuracy of RS and BCI was further assessed by 
Kaplan-Meier analysis. Figures 1 and 2 show cumulative Kaplan-Meier curves for 
10-year DR rates for the cross-classification between RS and BCI risk groups. BCI 
re-stratified both RS-low and RS-intermediate patients further into risk subsets with 
significantly differential risk of DR (LR-χ2=14.64, P<0.001 and LR-χ2=11.75, 
P=0.003, respectively; Figure 1A and 1B). Among the 388 women categorized by RS 
as low risk, 20 women were reclassified as being high risk by BCI and had a DR risk 
of 23.3% by 10 years, which incurs a 7 times higher risk of distant recurrence 
compared with those reclassified as the BCI-low risk group (HR=6.77 (2.12-21.58); 
Figure 1A). Those reclassified into the intermediate risk group by BCI had a three 
times higher risk of DR than those in the low RS risk group (HR=2.94 (1.16-7.46)) 
with a 10-year risk of DR of 12.2% (Figure 1A). Similarly, among the 178 women 
classified by RS as intermediate risk, 95 women were downgraded to low risk by BCI 
with a 10-year DR risk of 7.1% in contrast to 34 women who were upgraded to high 
risk by BCI with a 10-year DR risk of 27.8% (Figure 1B). Among women classified by 
RS as intermediate risk, those classified by BCI as intermediate or high risk group 
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had a 4 to 5 times actual higher risk of distant recurrence by 10 years than those 
classified by BCI as low risk (HR=3.80 (1.40-10.27) and HR=4.83 (1.72-13.59), 
respectively) (Figure 1B). Among the 99 women categorized by RS as high risk, 12 
were reclassified by BCI as low risk with a non-significantly lower risk of DR than 
those in the intermediate and higher risk groups, (Figure 1C). However, no 
significant reclassification of any of the BCI risk groups by the RS was observed in 
terms of 10-year DR risk (Figure 2). 
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Discussion 
 
As Wwe have previously shown reported [13], that the linear BCI added significant 
prognostic information for distant recurrence beyond that of clinical parameters and 
the Oncotype Dx RS for overall cumulative risk of 10 year DR in HR+, lymph-node 
negative breast cancer [13] in the TransATAC population. Further analysisOur 
results showed that BCI re-categorized patients within low and intermediate RS risk 
groups in a statistically significant manner. In contrast, RS did not significantly re-
classify any of the risk groups identified by BCI. This was also reflected in the 
significant net reclassification index of 10.9% for BCI vs. RS. 
BCI is a gene expression–based signature that algorithmically integrates the 
differential expression of 5 cell cycle related genes (MGI), and the expression ratio of 
HOXB13/IL17BR (H/I) [10]. BCI has been shown to be a significant prognostic factor 
in women with hormonal receptor-positive, lymph-node negative disease for both 
early (0-5 years) and late (5-10 years) follow-up periods[10, 13]. RS is based on a 
21-gene signature that was developed in a tamoxifen-treated, lymph node negative 
population, and is in part driven by proliferation genes [7, 15]. The RS has shown to 
be a strong prognostic marker particularly in the early follow-up period (0-5 years) 
[16]. Although functionally similar in the ability of the two scores to profile mitogenic 
activity, there is no overlap in the gene characteristics between RS and BCI. The 
correlation between BCI and RS or CTS was weak (rho=0.49, rho=0.45, 
respectively) and therefore the significant additional prognostic information shown in 
our analysis by BCI is not accounted for by either clinical parameters or RS. Some 
comparative studies have shown that multi-gene signatures provide comparable 
prognostic performance despite modest overlap [17, 18]. However, these studies 
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utilized public microarray datasets derived from tumor bank specimens, which may 
present selection bias with respect to the intended patient population. Here, we 
assessed the genomic signatures at the individual patient level data with clinical 
outcome from the TransATAC study. 
Results of this study may have implications for clinical decision making related to 
early stage breast cancer and potential disease management. For example, patients 
in the RS low risk group are generally considered to have a favorable prognosis with 
5 years of endocrine therapy alone and are unlikely to benefit from adjuvant 
chemotherapy [7, 8]. Recent data from the TAILORx trial has confirmed the excellent 
prognosis for patients with the lowest RS scores (0-10) over the first 5 years post-
diagnosis [19]. However, in the present study, BCI identified approximately 22% of 
RS low risk patients as intermediate risk and 5% as high risk. These findings suggest 
that a significant proportion of RS low risk patients are at an elevated risk of late 
recurrence, and may benefit from extended endocrine therapy. Notably, the H/I 
component of the BCI test has been shown to be predictive of benefit from extended 
endocrine therapy in the MA.17 trial [11]. BCI also re-categorized women who were 
classified by RS into the high risk into a low risk group. Although some of these 
women had large and poorly differentiated tumors, the low risk of DR overall is an 
indication that the benefit of additional endocrine or adjuvant chemotherapy is 
uncertain is this group. We have previously published data on cross-classification by 
the CTS and PAM50 ROR in the TransATAC study [20] where the ROR categorised 
more women into the high risk group than the CTS alone. Both of these findings 
suggest the importance of non-clinical tumor characteristics, such as biology of these 
tumors, that need to be taken into account when assessing DR risk, specifically after 
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5 years of endocrine treatment [16]. Finally, BCI significantly re-stratified the RS 
intermediate risk group, a categorization that presents challenges for clinical 
decision-making, identifying approximately half of these patients as having a low risk 
of recurrence and half with an elevated risk of recurrence. Of note, the subset of 
patients re-stratified by BCI as intermediate or high risk appeared to have an 
elevated risk for both early and late recurrences; in contrast to those categorised to 
low risk groups by BCI or RS. While not evaluated in this study, these results 
suggest a potential role for both adjuvant chemotherapy and extended endocrine 
therapy that should be evaluated in future studies. RS cross stratification of the BCI 
intermediate risk group resulted in a trend towards statistical significance, with 
approximately half of patients downgraded to RS low risk. 
Strengths of this analysis are the large sample size of women with lymph-node 
negative disease, with a median follow-up of 10 years. Furthermore, this patient 
population comes from a well described clinical trial using both tamoxifen and 
anastrozole. Limitations of this studyOur study has limitations. are thatinclude that 
oOnly a subset of the patients (n=665) from the main ATAC trial were included in this 
analysis (N=665) of whom 10.8% had a distant recurrence. Secondly, none of these 
women have received chemotherapy and therefore our results may not apply to 
chemotherapy-treated women. Of note, patients with a high RS would receive 
adjuvant chemotherapy and therefore have a lower risk of distant recurrence. 
FurthermoreFinally, this analysis focused on women with lymph-node negative 
disease and therefore our results are not applicable to women with lymph-node 
positive disease. 
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In summary, this study confirmed that linear BCI provided statistically significant 
prognostic information in addition to traditional clinical factors and RS in women with 
HR+, lymph-node negative disease treated with adjuvant endocrine therapy. New 
findings from this analyses are that the BCI re-classifies quite a few women into 
different risk categories than RS, and that these reclassifications were associated 
with substantial differences in patient outcomes. Therefore, our findings on the 
prognostic value of BCI may have potential clinical impact with respect to improving 
individualized risk stratification for patients with lymph-node negative early stage 
breast cancer. 
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Figure legends 
Figure 1: Kaplan-Meier analysis for 10-year distant recurrence rates in BCI risk 
groups within RS-Low (N=388, Figure 1A), RS-Intermediate (N=178, Figure 1B), and 
RS-High (N=99, Figure 1C) risk groups. Distant recurrence differences were 
evaluated by log-rank test. 
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Figure 2: Kaplan-Meier analysis for 10-year distant recurrence rates in RS Risk 
Groups within BCI-Low (N=390, Figure 2A), BCI-Intermediate (N=166, Figure 2B), 
and BCI-High (N=109, Figure 2C) risk groups. Distant recurrence differences were 
evaluated by log-rank test. 
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Table 1: Hazard ratio and likelihood ratio tests for BCI and RS (LR-χ2) in the 
unvariate analysis and for both scores when added to the CTS and other score 
(∆LR-χ2) in the multivariableriate analysis. 
 
 
 HR (95% CI) LR-χ2  
(P-value) 
RS 1.64 (1.39-1.94) 25.16 
(<0.0001) 
BCI 3.24 (2.31-4.54) 48.96 
(<0.0001) 
  ∆LR-χ2  
(P-value) 
CTS+RS+BCI 2.00 (1.32-3.05) 11.09 
(0.0009) 
CTS+BCI+RS 1.20 (0.95-1.50) 2.22 
(0.1) 
RS=Oncotype DX Recurrence Score; BCI=Breast Cancer Index, CTS=Clinical Treatment Score; HR=Hazard Ratio; 
LR=Likelihood Ratio 
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Table 2: Cross-stratification of women into respective risk groups by RS and BCI. 
(Grey shaded area=reclassified into higher risk groups by BCI, blue shaded 
areas=reclassified into lower risk groups by BCI) 
 RS 
BCI Low Intermediate High Total 
Low 283 95 12 390 
Intermediate 85 49 32 166 
High  20 34 55 109 
Total  388 178 99 665 
RS=Oncotype DX Recurrence Score; BCI=Breast Cancer Index 
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Table 3: Cross-stratification and Net Reclassification Index (NRI) of distant 
recurrence and non-events by BCI and RS. (Grey shaded area=reclassified into high 
risk groups by BCI, blue shaded areas=reclassified into lower risk groups by BCI) 
 
Distant recurrence (N=72) 
    RS 
BCI Low Intermediate High 
Low 10 6 1 
Intermediate 8 11 7 
High 4 9 16 
    Non-events (N=593) 
    RS 
BCI Low Intermediate High 
Low 273 89 11 
Intermediate 77 38 25 
High 16 25 39 
RS=Oncotype DX Recurrence Score; BCI=Breast Cancer Index 
 
reclassified into higher risk group by BCI 
  reclassified into lower risk group by BCI 
  
 NRI=[distant recurrence (% upward - % downward)]–[non-events (% upward- % downward)] 
 NRI for (BCI/RS)=[(21/72)-(14/72)]–[(118/593)-(125/593)]=10.9% 
 
